Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660225 · ClinicalTrials.gov registry record · NA
Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder
A NA study, sponsored by Nader Pouratian.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT06660225 is a NA study that is actively recruiting participants, run by Nader Pouratian. The registered enrollment target is 10 participants.
The verdict
NCT06660225, a NA study, is actively recruiting participants, sponsored by Nader Pouratian.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if deep brain stimulation (DBS) works to treat refractory obsessive-compulsive disorder (OCD). The main questions it aims to answer are: * Assess the effects of the anteromedial sub-thalamic nucleus (amSTN)stimulation on obsessive/compulsive symptoms. * Map the amSTN using neuronal responses \[single unit and local field potentials (LFP) recordings\] at rest and under high frequency stimulation during surgery. * Record chronic brain activity with the implanted pulse generator and look for neuronal signatures correlated with symptom severity. Researchers will compare active deep brain stimulation to a placebo (sham stimulation) to see if DBS works to treat refractory OCD. Participants will: * Undergo surgery for the implantation of a deep brain stimulation device * Follow-up visits every three weeks with study staff * 6 month follow-up for the next 2-3 years after first year of study participation is complete
Interventions
- DEVICE Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]
- DEVICE Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-06 |
| Est. Completion | 2031-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660225
The ClinicalTrials.gov registry entry for NCT06660225 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nader Pouratian, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation] is the first listed.
NCT06660225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06660225 about?
NCT06660225 is a clinical study titled "Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder". The goal of this clinical trial is to learn if deep brain stimulation (DBS) works to treat refractory obsessive-compulsive disorder (OCD). The main questions it aims to answer are: * Assess the effects of the anteromedial sub-thalamic nucleus (amSTN)stimulation on obsessive/compulsive symptoms. * M...
What is the current status of trial NCT06660225?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-06. Estimated completion is 2031-01.
What interventions are being tested in trial NCT06660225?
The interventions under investigation include: Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation] (DEVICE), Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation] (DEVICE).
Who is sponsoring clinical trial NCT06660225?
This trial is sponsored by Nader Pouratian, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.